Qynapse utilizes AI-driven neuroimaging software, QyScore®, to automate the analysis and quantification of MRI scans for central nervous system diseases, enhancing diagnostic accuracy to over 90%. This technology addresses the high misdiagnosis rate in CNS disorders, enabling timely interventions and improved patient outcomes.
Funding
$170K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Central nervous system (CNS) disorders such as Alzheimer's, multiple sclerosis, and Parkinson's disease often face high misdiagnosis rates due to the complexity of neuroimaging analysis. Inaccurate or delayed diagnoses can hinder timely interventions and negatively impact patient outcomes. Traditional methods of assessing MRI scans can be subjective and time-consuming, leading to variability in interpretation.
Solution
Qynapse offers QyScore, an AI-powered neuroimaging software platform designed to automate the analysis and quantification of MRI scans for CNS diseases. The platform aims to provide clinicians and researchers with objective and precise measures of neurodegeneration and neuroinflammation. By applying advanced algorithms to brain images, QyScore generates actionable insights that support more accurate diagnoses and monitoring of disease progression. This technology facilitates timely interventions, potentially improving patient outcomes and aiding pharmaceutical companies in clinical trials.
Target Audience
The primary target audience includes physicians, radiologists, and researchers specializing in CNS disorders, as well as pharmaceutical companies conducting clinical trials for related therapies and payers.
Features
- Automated labeling, visualization, and volumetric quantification of brain structures and lesions from MRI scans
- AI-powered analysis to identify subtle changes indicative of CNS disorders
- Comparison of volumetric data to a normative dataset of over 10,000 brain scan images
- Identification and quantification of over 200 automated measures of neuroinflammation and neurodegeneration
- FDA-cleared and CE-marked for clinical use
- QyPredict (research-use-only) combines genomics, biofluids, neuroimaging, and cognitive endpoints to predict disease trajectory
- Compliant with ISO 13485, ISO/IEC 27001, HDS, HIPAA, GDPR, and 21 C.F.R. Part 11 standards